Mylan N.V. announced that in connection with the Combination of Mylan with Pfizer’s off-patent branded and generic established medicines business, effective as of November 16, 2020, (a) Heather Bresch retired as Chief Executive Officer of Mylan, (b) Rajiv Malik (President), Paul Campbell (Chief Accounting Officer) and Anthony Mauro (Chief Commercial Officer) ceased to be officers of Mylan and (c) Heather Bresch, Robert J. Cindrich, Robert J. Coury, JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish, Pauline van der Meer Mohr, Randall L. (Pete) Vanderveen and Sjoerd S. Vollebregt ceased to be directors of Mylan.